TRANYLCYPROMINE

Course overview

THE MAIN FDA-APPROVED INDICATION OF TRANYLCYPROMINE IS FOR MAJOR DEPRESSIVE DISORDER WITHOUT MELANCHOLIA. THE NON-FDA-APPROVED INDICATIONS FOR THIS MEDICATION INCLUDE TREATMENT-RESISTANT DEPRESSION, TREATMENT-RESISTANT SOCIAL ANXIETY DISORDER, TREATMENT-RESISTANT PANIC DISORDER, AND ATYPICAL DEPRESSION. ATYPICAL DEPRESSION CONSISTS OF HYPERPHAGIA, HYPERSOMNIA, REJECTION SENSITIVITY, AND LEADEN PARALYSIS ACCOMPANYING THE DEPRESSION. THIS ACTIVITY OUTLINES THE INDICATIONS, MECHANISM OF ACTION, METHODS OF ADMINISTRATION, SIGNIFICANT ADVERSE EFFECTS, CONTRAINDICATIONS, TOXICITY, AND MONITORING, OF TRANYLCYPROMINE SO PROVIDERS CAN DIRECT PATIENT THERAPY WHERE IT IS INDICATED AS PART OF THE INTERPROFESSIONAL TEAM.